Life Sciences Transactions

We represent life sciences clients in the full-array of mission-critical transactions, including licensings, collaborations, financings, joint ventures, and mergers and acquisitions. Our clients range from startups to emerging biotechs to established global pharmaceutical companies, as well as venture capital, private equity, and investment banking firms focused on the life sciences industry.

Our life sciences transactions team helps clients build, negotiate, and implement essential strategic transactions with other pharmaceutical, biotech, and diagnostic companies, as well as the academic, government, and nonprofit sectors. We leverage our industry-specific experience to advise clients on transactions to research, develop, and commercialize products and technologies.

Our life sciences transactions experience ranges from early-stage licensing and research deals to strategic development and commercialization collaborations to mergers and acquisitions, public offerings and other exit events. In the course of structuring and negotiating transactions, we provide a wide variety of legal services, including intellectual property, US Food and Drug Administration/regulatory issues, antitrust, tax, and US and global governmental regulations. We assist clients with operational matters such as supply, distribution, clinical trial, and co-promotion agreements, as well as equity investment agreements. We also represent academic institutions and industry partners in licensing technology and sponsored research programs.

Our lawyers represent life sciences companies on product-related acquisitions and divestitures as well as public and private mergers and acquisitions. We handle transactions of varying sizes and of all different types, including asset purchases, stock purchases, tender offers, proxy contests, restructurings, leveraged buyouts, and going-private transactions. We also represent investment banks and commercial banks, venture capital firms, private equity firms, institutional lenders, independent director committees, and management groups in matters related to mergers and acquisitions.

Our team also advises private equity and venture capital firms, as well as nonprofits, on fund formation and other investment vehicles, and we counsel pharmaceutical clients on their participation in these funds.

Globally, our clients include the following:

  • 17 of the top 20 pharmaceutical companies (Source: Pharmaceutical Executive)
  • Eight of the top 20 biotechnology companies (Source: Genetic Engineering & Biotechnology News)
  • 13 of the top 20 medical device companies (Source: Medical Product Outsourcing)